PERSERIS KIT

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PERSERIS KIT (PERSERIS KIT).

How it works

Risperidone, the active component of PERSERIS, is an atypical antipsychotic with antagonist activity at dopamine D2 and serotonin 5-HT2A receptors. It also binds to α1-adrenergic, α2-adrenergic, and histamine H1 receptors.

What the body does with it

Metabolism	Risperidone is extensively metabolized in the liver via CYP2D6 and CYP3A4 isoenzymes to 9-hydroxyrisperidone (paliperidone), the major active metabolite.
Excretion	Primarily hepatic metabolism via CYP2D6 and CYP3A4; approximately 30-40% of a dose is excreted in urine as metabolites, with less than 1% as unchanged drug. Biliary/fecal elimination accounts for about 60-70%.
Half-life	Terminal elimination half-life is approximately 15 days (range 10-20 days) for the extended-release injectable formulation, reflecting slow release from the depot and sustained plasma concentrations.
Protein binding	Approximately 95% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Apparent volume of distribution is about 7-10 L/kg, indicating extensive extravascular distribution and high tissue binding.
Bioavailability	Subcutaneous injection: 100% for the sustained-release formulation. Immediate-release oral formulations have approximately 40% bioavailability due to first-pass metabolism, but the depot is fully absorbed.
Onset of Action	Subcutaneous injection: Clinical antipsychotic effect is typically observed within 4-7 days post-injection, aligning with the attainment of steady plasma levels.
Duration of Action	Following a single 90 mg or 120 mg subcutaneous injection, therapeutic plasma concentrations are maintained for approximately 1 month, supporting monthly dosing intervals.

Classification & Brands

Dosing & administration

Subcutaneous injection: 90 mg every 28 days for maintenance treatment of schizophrenia.

Dosage form	FOR SUSPENSION, EXTENDED RELEASE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Severe renal impairment (CrCl <30 mL/min) has not been studied; use with caution.
Liver impairment	Mild hepatic impairment (Child-Pugh A): No dose adjustment; moderate to severe (Child-Pugh B or C): Not studied; avoid use.
Pediatric use	Safety and efficacy not established in pediatric patients.
Geriatric use	Elderly patients (≥65 years): Dose selection should be cautious, starting at the low end of the dosing range, reflecting greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease or other drug therapy.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PERSERIS KIT (PERSERIS KIT).

Breastfeeding

Risperidone and its active metabolite 9-hydroxyrisperidone are excreted in human breast milk. M/P ratio not established. Low relative infant dose (estimated RID ~4-9% of weight-adjusted maternal dose). Consider benefits of breastfeeding vs potential for adverse effects (sedation, weight gain, developmental delays); monitor infant for these effects.

Teratogenic Risk

PERSERIS (risperidone) is Pregnancy Category C. First trimester: Limited data; animal studies show increased fetal resorptions and malformations at doses >2 times human dose. Second and third trimesters: Cases of extrapyramidal symptoms and withdrawal (e.g., agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder) in neonates exposed during late pregnancy. Neonatal monitoring recommended.

Warnings & precautions

■ FDA Black Box Warning

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. PERSERIS is not approved for the treatment of patients with dementia-related psychosis.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to risperidone or paliperidone","Concurrent use with drugs known to prolong QT interval (relative)"]

Clinical Precautions

Precautions

["Cerebrovascular adverse events in elderly patients with dementia-related psychosis","Neuroleptic malignant syndrome (NMS)","Tardive dyskinesia","Hyperglycemia and diabetes mellitus","Orthostatic hypotension","Leukopenia, neutropenia, and agranulocytosis","Seizures","QT interval prolongation","Weight gain and metabolic changes"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

PERSERIS KIT

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PERSERIS KIT (PERSERIS KIT).

How it works

What the body does with it

Metabolism	Risperidone is extensively metabolized in the liver via CYP2D6 and CYP3A4 isoenzymes to 9-hydroxyrisperidone (paliperidone), the major active metabolite.
Excretion	Primarily hepatic metabolism via CYP2D6 and CYP3A4; approximately 30-40% of a dose is excreted in urine as metabolites, with less than 1% as unchanged drug. Biliary/fecal elimination accounts for about 60-70%.
Half-life	Terminal elimination half-life is approximately 15 days (range 10-20 days) for the extended-release injectable formulation, reflecting slow release from the depot and sustained plasma concentrations.
Protein binding	Approximately 95% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Apparent volume of distribution is about 7-10 L/kg, indicating extensive extravascular distribution and high tissue binding.
Bioavailability	Subcutaneous injection: 100% for the sustained-release formulation. Immediate-release oral formulations have approximately 40% bioavailability due to first-pass metabolism, but the depot is fully absorbed.
Onset of Action	Subcutaneous injection: Clinical antipsychotic effect is typically observed within 4-7 days post-injection, aligning with the attainment of steady plasma levels.
Duration of Action	Following a single 90 mg or 120 mg subcutaneous injection, therapeutic plasma concentrations are maintained for approximately 1 month, supporting monthly dosing intervals.

Classification & Brands

Dosing & administration

Subcutaneous injection: 90 mg every 28 days for maintenance treatment of schizophrenia.

Dosage form	FOR SUSPENSION, EXTENDED RELEASE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Severe renal impairment (CrCl <30 mL/min) has not been studied; use with caution.
Liver impairment	Mild hepatic impairment (Child-Pugh A): No dose adjustment; moderate to severe (Child-Pugh B or C): Not studied; avoid use.
Pediatric use	Safety and efficacy not established in pediatric patients.
Geriatric use	Elderly patients (≥65 years): Dose selection should be cautious, starting at the low end of the dosing range, reflecting greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease or other drug therapy.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PERSERIS KIT (PERSERIS KIT).

Breastfeeding

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to risperidone or paliperidone","Concurrent use with drugs known to prolong QT interval (relative)"]